A Novel Beads-free CAR T-Cell Manufacturing Platform

Chimeric antigen receptors (CARs) T-cell therapy has become an important approach for cancer treatment. This project aims develop a novel perfusion-based, beads-free, bioreactor system as a new platform for CAR T cell manufacturing.
Categories
Cell and Gene therapies
Project status
100% Completed

Industry Need

Chimeric antigen receptors (CARs) T-cell therapy has become an important approach for cancer treatment.

Solution

Develop a novel perfusion-based, beads-free, bioreactor system as a new platform for CAR t-cell manufacturing.

Outputs/Deliverables

Developed an automatable, scalable, and closed bioreactor system and process for T-cell activation and expansion.

Impacts

The development of this novel perfusion-based system would facilitate scaling the manufacturing of CAR T cells for different users.

Publications

Additional Project Information (Members Only)

Login to the NIIMBL member portal to access more, including: 

  • Updates
  • Value Proposition
  • Related Publications
  • Deliverables

Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

Project Lead

Southwest Research Institute

Southwest Research Institute

Participating Organizations

Genentech, Inc.

Genentech, Inc.

Merck Sharp & Dohme LLC

Merck Sharp & Dohme LLC

University of Pennsylvania
Xcellerate Biotech Inc.

Xcellerate Biotech Inc.